

Figure-1: Western blot analysis of A549 cells treated with erlotinib HCl and NRC 2694. Dose dependent decrease in EGFR levels was observed.




Figure-2: Matrigel invasion assay of H1299 cells treated with Erlotinib and NRC 2694. A dose dependent decrease in invasion was observed




Figure-3: Decrease in tumor size induced by oral and ip administration of Erlotinib HCl and NRC 2694 in nude mice implanted with A549 human lung tumors




Figure-4: Lungs harvested from nude mice with A549 luciferase expressing cells treated with various concentrations of Erlotinib HCl and NRC 2694 by oral or ip routes




Figure-5: Representative H&E stained sections of nude mice tumor bearing lungs after treatment with Erlotinib HCl and NRC 2694




Figure-6: Nude mice implanted with A549 luciferase expressing cells treated with various concentrations of erlotinib HCl by oral and ip routes




Figure-7: Nude mice implanted with A549 luciferase expressing cells treated with various concentrations of NRC 2694 by oral and ip routes




Figure-8: Study of the effect of NRC NCEs in relation to other receptors such as HER-1,2,3,4 and VEGFR *in vitro*
Decrease in levels of Erb1, ErbB2, ErbB3 and ErbB4 after treatment with NRC 2694 in A549 cells was observed